Insider filing · INBX

Mark Lappe bought $629K of Inhibrx Biosciences (INBX)

Executed Sep 12 2024, disclosed Sep 16 2024, 4 days later.

Over the 21 trading sessions from the disclosed entry session (Sep 16 2024), the stock returned -5.7% (delay-adjusted); from the execution session (Sep 12 2024), +4.1%. Derived: entry at the session's open, exit at the close 20 sessions later.

ML Mark Lappe Chief Executive Officer profile →

Mark Lappe (Chief Executive Officer) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Inhibrx Biosciences, Inc. (INBX). The largest single filing was $2.6M of INBX (24,500 sh across 5 lots, as filed), executed Sep 8. The median gap between execution and disclosure was 0 days.

INBX Inhibrx Biosciences, Inc. INBX · Healthcare · 7 filings in 24 months ticker →

Healthcare · Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→